Adams Diversified Equity Fund Inc. Purchases 11,800 Shares of Cencora, Inc. (NYSE:COR)

Adams Diversified Equity Fund Inc. grew its position in Cencora, Inc. (NYSE:COR) by 17.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 81,000 shares of the company’s stock after purchasing an additional 11,800 shares during the quarter. Adams Diversified Equity Fund Inc.’s holdings in Cencora were worth $18,199,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of COR. Swedbank AB boosted its stake in shares of Cencora by 2.3% in the 3rd quarter. Swedbank AB now owns 1,394,449 shares of the company’s stock valued at $313,863,000 after purchasing an additional 31,104 shares during the last quarter. United Bank lifted its position in shares of Cencora by 4.2% during the 3rd quarter. United Bank now owns 5,601 shares of the company’s stock valued at $1,261,000 after acquiring an additional 225 shares during the period. Mutual of America Capital Management LLC lifted its position in shares of Cencora by 2.9% during the 3rd quarter. Mutual of America Capital Management LLC now owns 21,528 shares of the company’s stock valued at $4,846,000 after acquiring an additional 605 shares during the period. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of Cencora during the 3rd quarter valued at $1,648,000. Finally, Avior Wealth Management LLC lifted its position in shares of Cencora by 66.5% during the 3rd quarter. Avior Wealth Management LLC now owns 6,004 shares of the company’s stock valued at $1,351,000 after acquiring an additional 2,398 shares during the period. 97.52% of the stock is owned by institutional investors.

Insider Transactions at Cencora

In other news, CEO Robert P. Mauch sold 4,970 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the transaction, the chief executive officer now owns 51,070 shares of the company’s stock, valued at $13,022,850. This represents a 8.87 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Lazarus Krikorian sold 2,000 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the transaction, the chief accounting officer now directly owns 20,154 shares in the company, valued at $5,241,249.24. This represents a 9.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,970 shares of company stock worth $2,998,670 in the last quarter. Insiders own 10.80% of the company’s stock.

Cencora Stock Performance

NYSE COR opened at $267.78 on Friday. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $268.91. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The firm has a market cap of $51.93 billion, a price-to-earnings ratio of 38.09, a PEG ratio of 1.31 and a beta of 0.51. The company has a fifty day moving average price of $250.01 and a 200-day moving average price of $239.87.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, equities research analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.82%. The ex-dividend date of this dividend was Friday, February 14th. Cencora’s payout ratio is 31.29%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on COR shares. Mizuho started coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price on the stock. JPMorgan Chase & Co. boosted their target price on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. StockNews.com upgraded shares of Cencora from a “hold” rating to a “buy” rating in a report on Wednesday, March 12th. Evercore ISI upped their price objective on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. Finally, Wells Fargo & Company upped their price objective on shares of Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a report on Friday, March 14th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, Cencora has a consensus rating of “Moderate Buy” and a consensus price target of $280.20.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.